In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Cue Biopharma (CUE – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $3.62.
Benjamin covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Cue Biopharma, and Sutro Biopharma. According to TipRanks, Benjamin has an average return of -11.6% and a 28.89% success rate on recommended stocks.
Cue Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $10.00.
See the top stocks recommended by analysts >>
CUE market cap is currently $154.6M and has a P/E ratio of -2.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
Read More on CUE:
